# signs and symptoms of dry eye disease in December 2022 FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022

> No upcoming FDA catalysts in signs and symptoms of dry eye disease in December 2022; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for signs and symptoms of dry eye disease in December 2022?

No upcoming FDA catalysts in signs and symptoms of dry eye disease in December 2022; 2 past events are recorded. SEC Form 10-Q: "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." [Calendar and source filings](https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022)

Source: SEC Form 10-Q, accession 0001193125-26-449742, https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-05. Cite: https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 27, 2023 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease in December 2022 | completed, complete response letter | "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm)) |
| November 27, 2023 | [Reproxalap NDA/BLA submission](https://sec-api.dev/pdufa/reproxalap) | ALDX | signs and symptoms of dry eye disease in December 2022 | completed | "We submitted an NDA (the Reproxalap NDA) for reproxalap for the treatment of the signs and symptoms of dry eye disease in December 2022 and on November 27, 2023, we announced that we had received a Complete Response Letter from the FDA regarding this filing (the 2023 Complete Response Letter)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1341235/000119312526449742/aldx-20260930.htm)) |

## Drugs

- [Reproxalap](https://sec-api.dev/pdufa/reproxalap) (ALDX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "signs and symptoms of dry eye disease in December 2022 FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022

```bibtex
@misc{secapidev_indications_signs_and_symptoms_of_dry_eye_disease_in_december_2022_20261116,
  title        = {signs and symptoms of dry eye disease in December 2022 FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_signs_and_symptoms_of_dry_eye_disease_in_december_2022_20261116","title":"signs and symptoms of dry eye disease in December 2022 FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/signs-and-symptoms-of-dry-eye-disease-in-december-2022","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
